BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 26083544)

  • 1. A new era of personalized medicine for cystic fibrosis - at last!
    Quon BS; Wilcox PG
    Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing the Paradigm - Treating the Basic Defect in Cystic Fibrosis.
    Guglani L
    Indian J Pediatr; 2015 Aug; 82(8):727-36. PubMed ID: 26077199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational research to enable personalized treatment of cystic fibrosis.
    Hagemeijer MC; Siegwart DJ; Strug LJ; Cebotaru L; Torres MJ; Sofoluwe A; Beekman JM
    J Cyst Fibros; 2018 Mar; 17(2S):S46-S51. PubMed ID: 29275953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating the genetics of cystic fibrosis to personalized medicine.
    Corvol H; Thompson KE; Tabary O; le Rouzic P; Guillot L
    Transl Res; 2016 Feb; 168():40-49. PubMed ID: 25940043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Challenges of personalized medicine for cystic fibrosis].
    Corvol H; Taytard J; Tabary O; Le Rouzic P; Guillot L; Clement A
    Arch Pediatr; 2015 Jul; 22(7):778-86. PubMed ID: 26021452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.
    Barry PJ; Ronan N; Plant BJ
    Semin Respir Crit Care Med; 2015 Apr; 36(2):287-98. PubMed ID: 25826594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Root Cause of Cystic Fibrosis.
    Trescott L; Holcomb J; Spellmon N; Mcleod C; Aljehane L; Sun F; Li C; Yang Z
    Curr Drug Targets; 2015; 16(9):933-44. PubMed ID: 25316272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of cystic fibrosis treatment.
    Carter SC; McKone EF
    Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis research topics featured at the 14th ECFS Basic Science Conference: Chairman's summary.
    Mall MA; Hwang TC; Braakman I
    J Cyst Fibros; 2018 Mar; 17(2S):S1-S4. PubMed ID: 29229473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Therapies to Correct the Cystic Fibrosis Basic Defect.
    Bergeron C; Cantin AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis - an example of personalized and precision medicine.
    Skov M; Hansen CR; Pressler T
    APMIS; 2019 May; 127(5):352-360. PubMed ID: 30761610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
    Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
    Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.
    Amaral MD
    Curr Drug Targets; 2011 May; 12(5):683-93. PubMed ID: 21039334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.
    Rubenstein RC
    Mol Diagn Ther; 2006; 10(5):293-301. PubMed ID: 17022692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized medicine in cystic fibrosis: dawning of a new era.
    Clancy JP; Jain M
    Am J Respir Crit Care Med; 2012 Oct; 186(7):593-7. PubMed ID: 22723294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystic fibrosis: a clinical view.
    Castellani C; Assael BM
    Cell Mol Life Sci; 2017 Jan; 74(1):129-140. PubMed ID: 27709245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CFTR: cystic fibrosis and beyond.
    Mall MA; Hartl D
    Eur Respir J; 2014 Oct; 44(4):1042-54. PubMed ID: 24925916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.